Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study.
Tünbekici S, Yuksel HC, Acar C, Sahin G, Orman S, Majidova N, Coskun A, Seyyar M, Dilek MS, Kara M, Dıslı AK, Demir T, Kolkıran N, Sahbazlar M, Demırcıler E, Kuş F, Aytac A, Menekse S, Yucel H, Biter S, Koseci T, Unsal A, Ozveren A, Sevınc A, Goker E, Gürsoy P. Tünbekici S, et al. Among authors: biter s. Cancers (Basel). 2024 Dec 27;17(1):46. doi: 10.3390/cancers17010046. Cancers (Basel). 2024. PMID: 39796675 Free PMC article.
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.
Sekmek S, Ozsan Çelebi SN, Bayram D, Erol C, Kos FT, Sendur MAN, Altıntas YE, Tuylu T, Yildirim S, Biter S, Kıdı MM, Bayram E, Majidova N, Bayoglu IV, Atak M, Baskurt K, Akbas S, Alkan A, Bayramgil A, Aslan F, Sahin E, Balcik OY, Bayhan AZ, Saray S, Arpaci E, Ergun Y. Sekmek S, et al. Among authors: biter s. Sci Rep. 2024 Nov 30;14(1):29785. doi: 10.1038/s41598-024-81371-5. Sci Rep. 2024. PMID: 39616250 Free PMC article.
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study.
Kutlu Y, Dae SA, Yilmaz F, Erdem D, Sendur MAN, Akbas S, Senocak Tasci E, Bas O, Dane F, Sakin A, Kaya AO, Aykan MB, Ergun Y, Biter S, Disel U, Korkmaz M, Selcukbiricik F, Kose F, Olmez OF, Bilici A, Demir G, Yalcin S. Kutlu Y, et al. Among authors: biter s. Cancers (Basel). 2024 Jun 18;16(12):2251. doi: 10.3390/cancers16122251. Cancers (Basel). 2024. PMID: 38927957 Free PMC article.
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study.
Dülgar Ö, Türker S, Başaran G, Araz M, Sümbül AT, Çağlayan D, Gümüşay Ö, Biter S, Konca A, Özen M, Demir H, Özdemir M, Karataş F, Şahin E, Çavdar E, Yasin Aİ, Yaşar A, Derin S, Pehlivan M, Üyetürk Ü, Özdemir Ö, Kayıkçıoğlu E, Ak N, Şakalar T, Sakin A, Büyükşimşek M, Ay S, Ertürk İ, Akbaş S, Bir Yücel K, Gümüş M. Dülgar Ö, et al. Among authors: biter s. J Chemother. 2024 Jun 21:1-7. doi: 10.1080/1120009X.2024.2366683. Online ahead of print. J Chemother. 2024. PMID: 38904164
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A, Guven DC, Koksal B, Karaoglan BB, Kivrak D, Ismayilov R, Aslan F, Sutcuoglu O, Yazici O, Kadioglu A, Alan O, Majidova N, Erciyestepe M, Ozcan E, Akdag G, Taban H, Kaya AO, Guliyev M, Yildirim N, Sakalar T, Yazilitas D, Unal C, On S, Biter S, Demirci NS, Senler FC, Kemal Y, Halil OD, Gullu I, Aksoy S. Akyildiz A, et al. Among authors: biter s. Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4991-4999. doi: 10.1007/s00405-024-08744-4. Epub 2024 May 25. Eur Arch Otorhinolaryngol. 2024. PMID: 38795147 Free PMC article.
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ, Kutlu Y, Mutlu E, Aykan MB, Korkmaz M, Yalçın S, Şakalar T, Celayir ÖM, Kayıkçıoğlu E, Aslan F, Hafızoğlu E, Altıntaş YE, Keskinkılıç M, Chalabiyev E, Çelebi A, Dursun B, Kapar C, Özen M, Acar Ö, Dülgar Ö, Kut E, Biter S, Kus F, Almuradova E, Erdoğan AP, Saray S, Güven DC, Şimşek ET, Üskent N, Kemal Y, Çakar B, Açıkgöz Ö, Kılıçkap S, Aksoy S. Yıldırım HÇ, et al. Among authors: biter s. Int J Clin Oncol. 2024 Mar;29(3):258-265. doi: 10.1007/s10147-023-02460-5. Epub 2024 Feb 4. Int J Clin Oncol. 2024. PMID: 38310597